Engineered high-affinity human T cell receptors

Sheena N Smith; Daniel Thomas Harris; David M Kranz

Engineered high-affinity human T cell receptors

Sheena N Smith (Inventor), Daniel Thomas Harris (Inventor), David M Kranz (Inventor)

Biochemistry

Research output: Patent

Abstract

T cell receptors (TCRs) that have higher affinity for the Survivin antigen are provided. The high affinity TCRs were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the engineered TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.

Original language	English (US)
U.S. patent number	10023625
Filing date	11/21/14
State	Published - Jul 17 2018

Library availability

Discover UIUC Full Text

Cite this

@misc{e58da9da9f9c499393316a44d8f4a1f3,

title = "Engineered high-affinity human T cell receptors",

abstract = "T cell receptors (TCRs) that have higher affinity for the Survivin antigen are provided. The high affinity TCRs were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the engineered TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.",

author = "Smith, {Sheena N} and Harris, {Daniel Thomas} and Kranz, {David M}",

note = "STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This disclosure was made with U.S. Government support under Grant numbers R01 GM55767 and T32 GM070421, awarded by the National Institutes of Health. The U.S. Government has certain rights in the disclosure.; 10023625",

year = "2018",

month = jul,

day = "17",

language = "English (US)",

type = "Patent",

}

TY - PAT

T1 - Engineered high-affinity human T cell receptors

AU - Smith, Sheena N

AU - Harris, Daniel Thomas

AU - Kranz, David M

N1 - STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT This disclosure was made with U.S. Government support under Grant numbers R01 GM55767 and T32 GM070421, awarded by the National Institutes of Health. The U.S. Government has certain rights in the disclosure.

PY - 2018/7/17

Y1 - 2018/7/17

N2 - T cell receptors (TCRs) that have higher affinity for the Survivin antigen are provided. The high affinity TCRs were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the engineered TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.

AB - T cell receptors (TCRs) that have higher affinity for the Survivin antigen are provided. The high affinity TCRs were engineered through the generation of mutational libraries of TCRs in a single-chain format, followed by selection for improved stability and affinity on the surface of yeast (i.e. directed evolution). In embodiments, the engineered TCRs can be used in soluble form for targeted delivery in vivo, or as genes introduced into T cells in an adoptive T cell setting.

M3 - Patent

M1 - 10023625

Y2 - 2014/11/21

ER -

Engineered high-affinity human T cell receptors

Abstract

Library availability

Fingerprint

Cite this